Abstract

*S. Baldé, S. Bouteyeb, C. Elm’hadi, ML Sow, B. El Ghissassi, H. M’rabti and H. Errihani

ABSTRACT

Introduction: Crizotinib is a multi-target tyrosine kinase inhibitor against ALK, HGFR.CM and ROS1. IT is a new therapeutic standard for chest oncology prescribed. In non-small cell lung cancer with ALK-EML rearrangement its use is not devoted to side effects some of which are little described and under a special management. We report the case of a patient with Bronchospasm induced by this molecule as well as the modalities of management. Clinic Case: It is about 53 years old patient treated with anticoagulant for pulmonary embolism followed since 2013 for metastatic bronchial adenocarcinoma with bone with mutated EGFR having received Paclitaxel-carboplatin-bevacizumab induction chemotherapy with excellent tolerance. A clinical and radiological progression retained in front of the appearance of pulmonary and pleural metastatic motivated the realization of a new biopsy in search of a mutation of resistance. Molecule screening showed the presence of C-MET amplification and the patient was placed under crizotinib ofter two months of care. The patient has presented exacerbation of symptomatology respiratory one without majoration of radiological lesions and dyspnea stage III has amended under B2 mimetic and corticotherapy and stop crizotinib. Conclusion: Broncospasm under crizotinib although little reported (2-4%) of the cases can be life threatening. The management is rather based on prevention by B2 mimetic and corticosteroid therapy.